Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of
TAK · NYSE
- Prev Close
- $16.56
- Market Cap
- $52.42B
- Open
- —
- Trailing P/E
- —
- Day Range
- $16.78 - $16.57
- 52W Range
- $18.90 - $12.99
- Forward P/E
- —
- EPS
- —
- Volume
- 2.22M
- Dividend Yield
- —
- Beta
- —
- Avg Volume
- 1.14M
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of
Takeda Pharmaceutical is a global pharmaceutical company that develops and sells prescription medicines. The supplied evidence identifies a portfolio of core brands, newer products, and mature products, with growth from the first two categories offsetting expected declines in the last. It therefore makes money primarily through pharmaceutical product sales, although the evidence does not provide segment-level contributions, geographic mix, customer breakdown, revenue, or employee figures. Its customers are not specified beyond the healthcare markets served by its medicines. The company’s current operating scale and detailed therapeutic-area mix are also unavailable in the supplied material.
Notable Price Movement
- Aug 3-7$16.563.10%
Takeda fell $0.96, or 5.48%, over the supplied trading window, from $17.52 to $16.56. The stock initially gained to $17.75 on July 29, then reversed lower, closing at $17.25 on July 30 and $17.09 on July 31 before extending the decline to $16.83 on August 3 and $16.56 on August 4. The supplied earnings-call highlight said first-quarter fiscal 2026 results were in line with the full-year outlook, with growth from core brands and newer products largely offsetting expected declines in the mature portfolio. That broadly balanced update did not prevent the late-week selloff. No additional company-specific catalyst or market-wide driver is identified in the evidence.
Stories & Analysis
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Takeda And Indonesia Announce Plasma Collaboration To Build ASEAN's First Regional HubIs ADMA Stock's 13.5% Monthly Gain a Sign of Recovery?DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?
